Monoclonal antibodies have already established a secure position as a very promising strategy for therapeutics. Advances in genetic engineering have enabled to generate human antibodies which circumvent the problems of using murine antibodies in human therapy. High specificity and high affinity are attractive characteristics of antibodies which make them suitable for clinical applications. Neutralization of antigens, immunological effects, specific delivery of antibody conjugate to target cells, and direct effects through receptor engagement by antibodies have been exploited as mechanisms which generate antibody activity. Here, data will be presented on a series of human antibodies generated using the KM MouseTM that demonstrates desirable characteristics for therapeutic use including robust biological activity and low toxicity. The preclinical data for agonistic and antagonistic antibodies to TNF receptor super family members including TRAIL-R2 and CD40, will be presented. In addition, neutralizing antibody against influenza virus M2 protein will be also presented.
저자
Shiro Kataoka [ Ph. D Business Development Department, Kirin Pharma Co., Ltd., Japan ]
한국생물공학회 [The Korean Society for Biotechnology and Bioengineering]
설립연도
1984
분야
공학>생물공학
소개
이 법인은 생물 공학의 발전과 보급에 이바지하고, 회원 상호 간의 연구 협력과 친목을 도모함을 목적으로 한다
1. 생물공학 분야의 발전을 위한 연구 협력
2. 생물공학의 실용화를 촉진시키기 위한 산학 협동
3. 학술연구 발표회, 강연회, 연수회 등 학술활동의 개최
4. 국,영문 학술지,소식지,학술회의 Proceedings 및 학술도서의 발간
5. 생물공학 발전을 위한 정책 건의
6. 기타 국제 교류 등 본 학회의 목적 달성을 위한 제반 활동